Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from Chardan Capital

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a report issued on Friday,Benzinga reports. They currently have a $6.00 price objective on the stock. Chardan Capital’s price objective suggests a potential upside of 217.46% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Scotiabank initiated coverage on shares of Gain Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research report on Monday, March 17th. Roth Mkm reiterated a “buy” rating and set a $7.00 target price on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Finally, Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Stock Down 8.7 %

GANX stock opened at $1.89 on Friday. The business has a 50 day moving average of $2.22 and a 200 day moving average of $2.06. The firm has a market cap of $50.13 million, a PE ratio of -1.72 and a beta of 0.14. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $4.04. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.07. On average, research analysts forecast that Gain Therapeutics will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

A number of large investors have recently added to or reduced their stakes in GANX. Sprott Inc. purchased a new position in shares of Gain Therapeutics in the 4th quarter worth $30,000. Benedict Financial Advisors Inc. bought a new position in Gain Therapeutics in the fourth quarter valued at about $35,000. Bridgeway Capital Management LLC bought a new position in Gain Therapeutics in the fourth quarter valued at about $65,000. Northern Trust Corp boosted its position in Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after purchasing an additional 39,642 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its stake in shares of Gain Therapeutics by 83.6% during the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after purchasing an additional 44,750 shares during the period. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.